Payment overview · 2025
General Payments
$1,515.10
83 reported records · 23 companies
Healthcare provider profile · identity verified
Joseph Hunter Woolley, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT GEORGE, UT · NPI 1780800813
Verified facts
What the public records show
CMS Open Payments records show Joseph Hunter Woolley, M.D. received $1,515.10 in general payments during 2025 across 83 reported records.
ABBVIE INC. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $230.37 | 15.2% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $207.03 | 13.7% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $190.35 | 12.6% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $122.48 | 8.1% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $92.41 | 6.1% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $82.76 | 5.5% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.02 | 4.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.43 | 3.9% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $52.70 | 3.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.88 | 3.4% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $44.65 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.49 | 2.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.74 | 2.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.07 | 2.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.92 | 2.2% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $33.38 | 2.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.69 | 1.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.83 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.62 | 1.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.15 | 1.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $15.79 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.64 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.70 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,515.10 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $207.03 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $157.49 | 8 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $117.58 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.76 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $100.63 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.46 | 8 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $72.84 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $68.41 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $64.02 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.40 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.60 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $55.64 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $52.70 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $44.65 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.87 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.74 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $36.84 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| Artisan Normalized: artisan |
Device | Boston Scientific Corporation | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.98 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $10.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 108 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 187 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
187 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 37 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 700 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 636 | 169 |
| Losartan Potassium | Losartan Potassium | 444 | 132 |
| Omeprazole | Omeprazole | 397 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 338 | 107 |
| Lisinopril | Lisinopril | 322 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 310 | 87 |
| Gabapentin | Gabapentin | 286 | 95 |
| Spironolactone | Spironolactone | 268 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 86 |
| Trazodone Hcl | Trazodone Hcl | 195 | 51 |
| Allopurinol | Allopurinol | 189 | 48 |
| Mounjaro | Tirzepatide | 187 | 37 |
| Sertraline Hcl | Sertraline Hcl | 187 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 38 |
| Metformin Hcl | Metformin Hcl | 135 | 37 |
| Prednisone | Prednisone | 130 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 34 |
| Furosemide | Furosemide | 123 | 41 |
| Potassium Chloride | Potassium Chloride | 122 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 39 |
| Eliquis | Apixaban | 108 | 37 |
| Finasteride | Finasteride | 103 | 30 |
| Ozempic | Semaglutide | 103 | 24 |
| Simvastatin | Simvastatin | 100 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 29 |
| Montelukast Sodium | Montelukast Sodium | 88 | 25 |
| Estradiol | Estradiol | 87 | 27 |
| Synthroid | Levothyroxine Sodium | 86 | 24 |
| Jardiance | Empagliflozin | 83 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 25 |
| Ezetimibe | Ezetimibe | 76 | 27 |
| Carvedilol | Carvedilol | 73 | 24 |
| Alprazolam | Alprazolam | 71 | 23 |
| Fluconazole | Fluconazole | 70 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 68 | 14 |
| Bupropion Xl | Bupropion Hcl | 67 | 16 |
| Propranolol Hcl | Propranolol Hcl | 67 | 22 |
| Tramadol Hcl | Tramadol Hcl | 67 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 19 |
| Pregabalin | Pregabalin | 60 | 16 |
| Metformin Hcl Er | Metformin Hcl | 59 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 58 | 17 |
| Myrbetriq | Mirabegron | 58 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 58 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 17 |
| Torsemide | Torsemide | 52 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 19 |
| Farxiga | Dapagliflozin Propanediol | 50 | 15 |
| Valacyclovir | Valacyclovir Hcl | 49 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 16 |
| Linzess | Linaclotide | 48 | suppressed |
| Lorazepam | Lorazepam | 48 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 14 |
| Donepezil Hcl | Donepezil Hcl | 45 | 15 |
| Promethazine Hcl | Promethazine Hcl | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | 14 |
| Meloxicam | Meloxicam | 43 | 16 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 13 |
| Warfarin Sodium | Warfarin Sodium | 41 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 21 |
| Valsartan | Valsartan | 38 | 12 |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Anastrozole | Anastrozole | 37 | 13 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 13 |
| Gemtesa | Vibegron | 32 | suppressed |
| Methotrexate | Methotrexate Sodium | 32 | suppressed |
| Clonazepam | Clonazepam | 30 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 21 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Colestipol Hcl | Colestipol Hcl | 25 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Eplerenone | Eplerenone | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Amiloride Hcl | Amiloride Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 13 |
| Diazepam | Diazepam | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Levoxyl | Levothyroxine Sodium | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 16 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,515.10 · 83 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Artisan, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, CRYSVITA, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, General - Pain Management, Hillrom - Vest System Model 105 Home Care, INJECTAFER, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, TRINTELLIX, Tymlos, UBRELVY, VENASEAL, VRAYLAR, VYEPTI, WATCHMAN FLX, Wegovy, YUPELRI, ZENPEP, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error